Sentences with phrase «for calcium channels»

For calcium channels, Yue's and other research groups found that the resemblance element supports an important function, preventing the channel from opening when the cellular calcium level gets high.

Not exact matches

Your physician may prescribe Nifedipine, a calcium channel blocker, which helps increase blood flow and is safe for breastfeeding moms.

Isradipine, a drug recently shown to reduce the desire for alcohol, is a calcium - channel blocker normally used to treat high blood pressure.

Therefore, Lambert - Eaton syndrome IgG reacts with voltage - dependent calcium channels and blocks their function, a phenomenon that can account for the presynaptic impairment characteristic of this disorder.

These drugs, now in preliminary testing, seem to target the brain systems responsible for addiction One such medication, isradipine (Dynacirc), is a calcium - channel blocker most often prescribed for hypertension.

The researchers also identified the specific neuron responsible for detecting high pH. They did this by showing that when a specific sensing neuron, called the ASH neuron, was destroyed by laser microsurgery, the worms no longer avoided high pH. Going another step further, the researchers also identified some of the proteins involved in the response to high alkalinity, which make up a calcium channel.

In this study, the team, which included Dr. Meerim Nurbaeva and Miriam Eckstein in Dr. Lacruz's lab, for the first time used freshly dissected enamel cells (ameloblasts) from rodent teeth to modulate physiological processes in order to understand the contribution of CRAC channels in enamel calcium signaling.

The team found that the main calcium influx pathway involved in the mineralization of enamel [called the CRAC (Ca2 + release - activated Ca2 +) channel — the main type of SOCE (Store - operated Ca2 + entry) channel — is critical for controlling calcium uptake, which is necessary for the development of tooth enamel.

A team of researchers led by Rodrigo Lacruz, MSc, PhD, assistant professor in the Department of Basic Science and Craniofacial Biology at NYU College of Dentistry, has published a paper in Scientific Reports (5:15803) titled «Dental enamel cells express functional SOCE channels,» which reports the results of a study showing for the first time the mechanism of calcium transport essential in the formation of dental enamel.

The mutation resulted in a lower single channel conductance for calcium and a strongly increased conductance for sodium and potassium, indicating that glutamic acid - 95 is a crucial constituent of the ion selectivity filter.

Several years ago, when Feske and his colleagues were at another institution, they were the first to identify ORAI1, a new calcium channel, which is essential for calcium influx and T - cell function.

This led the researchers to a major conclusion, as Shigemoto explains: «Based on our results, we suggest that for each docking site, there is a corresponding cluster of voltage-gated calcium channels.

The study is meaningful in respect to the fact that it calls into question the role of the T - type calcium channel in the reticular thalamus, and is expected to provide an important theoretical foundation for understanding its role in the mechanism of absence seizures, as well as developing effective treatment methods for absence epilepsy.

Specifically, the bipolar neurons expressed more genes for membrane receptors and ion channels than non-bipolar cells, particularly those receptors and channels involved in the sending and receiving of calcium signals between cells.

Researchers at Johns Hopkins have spotted a strong family trait in two distant relatives: The channels that permit entry of sodium and calcium ions into cells turn out to share similar means for regulating ion intake, they say.

«We thought that the conflicting results for sodium channels might be related to difficulties in existing methods to control the calcium concentrations that might affect these channels,» Ben - Johny says.

A cryo — electron microscopy structure provides a framework for understanding function and disease mechanisms in a family of calcium channels.

Researchers have known for decades that some microorganisms, such as single - celled green algae, have proteins that respond to light by opening a channel in the microbe's membranes, allowing the passage of electrically charged ions (such as calcium and sodium).

The colorful snails yielded the first hint that these calcium channels could make a potent target for pain relief.

For years, scientists have been unsure how calcium ion channels function.

New atomic scale images of the structure of calcium's gatekeeper, IP3R, could go a long way toward solving this mystery and lead to treatments for the many diseases tied to channel malfunctions.

When the IP3R calcium channel receives signals, it creates a pathway for calcium ions to move across cell membranes.

The researchers studied calcium channels in neurons, which allow for the transport of calcium ions from one nerve cell to another, helping the cells transmit itch signals from the skin to other cells in the spinal cord.

In cells from sick hearts, these channels often don't inactivate properly, allowing for excess sodium entry and a build - up of calcium, which ultimately promotes abnormal heart rate (arrhythmia) and symptoms of heart failure.

For example, UT Southwestern's program was one of the first to use anti-lymphocyte antibodies to prevent and treat rejection; calcium channel blockers to improve the early function of transplanted kidneys; and molecular biology to better match donor kidneys with the patients who need them.

For instance, during their last month of life, a large proportion of older adults used platelet antiaggregants (45 %), beta - blockers (41 %), ACE inhibitors (21 %), vasodilators (17 %), statins (16 %), calcium channel blockers (15 %), or potassium - sparing agents (12 %).

17 [beta]- estradiol induced Ca2 + influx via L - type calcium channels activates the Src / ERK / cyclic - AMP response element binding protein signal pathway and Bcl - 2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen - induced neuroprotection.

Of these, SLC24A4 and CACNA1H are potential candidate genes for BP regulation, and the latter is a drug target for a class of calcium channel blockers.

Building on those findings, the Jans identified the genes for a different family of channels called calcium - activated chloride channels, which shuttle chloride ions to control smooth muscle contraction in the stomach, intestines, and lung airways.

A large observational study found that use of short - acting calcium channel blockers (CCBs) for hypertension is associated with increased incidence of pancreatic cancer among postmenopausal women, when compared with the use of other types of antihypertensive medication and never - use of such agents.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transcalcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transcalcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transCalcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Recently a study showed that damage to a muscle cell's calcium channels is a stimulus for mitochondrial biogenesis, the production of new mitochondria.

Excitable cells, such as skeletal muscle and nerve cells, contain voltage - dependent calcium channels in their cell membranes that allow for rapid changes in calcium concentrations.

Amlodipine, a calcium channel blocker, is the usual first choice for cats.

Dr. J was the first to use calcium channel blockers successfully in dogs and his pioneering treatments are used for many disorders in cats and dogs.

Two related potassium (K +) channel defects in benign familial neonatal convulsions (BFNC) have recently been identified.9 10 A defect in a receptor for a different neurotransmitter (acetylcholine) has previously been identified in a family with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 11, which was later shown to affect calcium (Ca +) movement.12 In humans, so far, there has not been any success in identifying genes associated with more common primary epilepsy syndromes such as juvenile absence epilepsy and juvenile myoclonic epilepsy (JME).13 No gene or marker linked to an epilepsy gene has been identified in any dog breed, as yet.

Neuromed was out, with Merck pulling out of a collaboration looking for NCE's targeting N - type calcium channels.

Most calcium channel blockers do not affect life insurance rates unless they were prescribed for chest pain (angina).